104 256

Cited 16 times in

Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes

Authors
 Yundeok Kim  ;  June-Won Cheong  ;  Yeo-Kyeoung Kim  ;  Ju-In Eom  ;  Hoi-Kyung Jeung  ;  Soo Jeong Kim  ;  Dohyu Hwang  ;  Jin Seok Kim  ;  Hyeuong Joon Kim  ;  Yoo Hong Min 
Citation
 PLOS ONE, Vol.9(2) : e86933, 2014 
Journal Title
 PLOS ONE 
Issue Date
2014
MeSH
Adult ; Aged ; Aged, 80 and over ; Biomarkers/blood ; Case-Control Studies ; DNA Methylation/genetics* ; Disease-Free Survival ; Female ; Gene Expression Regulation ; Humans ; Kaplan-Meier Estimate ; Male ; MicroRNAs/blood* ; MicroRNAs/genetics ; Middle Aged ; Multivariate Analysis ; Myelodysplastic Syndromes/blood* ; Myelodysplastic Syndromes/genetics* ; ROC Curve ; Reference Standards ; Treatment Outcome
Abstract
Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P = 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level (P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients.
Files in This Item:
T201400414.pdf Download
DOI
10.1371/journal.pone.0086933
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kim, Soo Jeong(김수정) ORCID logo https://orcid.org/0000-0001-8859-3573
Kim, Yun Deok(김윤덕) ORCID logo https://orcid.org/0000-0002-5336-7936
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Eom, Ju In(엄주인)
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
Jeung, Hoi Kyung(정회경)
Hwang, Doh Yu(황도유)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98191
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse